Figure 2.
Clinical presentation of (a) benign gingival hyperplasia in a patient in treatment with a BRAF inhibitor (vemurafenib); (b) a pigmentation of the hard palate induced by imatinib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.